作者: Nobuhiko Maeda , Masaharu Kamada , Toshifumi Daitoh , Masahiko Maegawa , Kohki Hirano
关键词: Prostate 、 Radioimmunoassay 、 Tumor marker 、 Endocrinology 、 Urology 、 Immunoglobulin binding 、 Adenoma 、 Antibody 、 Internal medicine 、 Prostate-specific antigen 、 Prostate cancer 、 Medicine
摘要: Human seminal plasma contains an immunoglobulin gamma binding factor (IgBF) with estimated molecular weight of 16 kD under reducing condition. IgBF was detected only in the prostate, including benign prostatic hypertrophy (BPH) and neoplasm. The present study performed to determine whether is a useful marker. Serum levels were measured patients tumors control without tumor by radioimmunoassay. prostatic-specific antigen (PSA), standard marker, also determined. prostate cancer significantly higher than those age-matched controls (P < 0.05). Also, BPH tended have elevated controls, although values not statistically significant. In patients, serum increased advancing age. There no correlation between PSA cancer. Using cut-off level at 28.5 ng/ml (2 S.D. above mean control), sensitivities 41.2% (7117) for cancer, 23.1% (6/26) BPH, 5.6% (1/18) patients. conclusion, marker diagnosis tumor, evaluating course treatment. © 1994 Wiley-Liss, Inc.